藍帆醫療(002382.SZ):2021年度擬申請授信額度不超14.425億元和2000萬歐元
格隆匯 12 月 4日丨藍帆醫療(002382.SZ)公佈,公司第五屆董事會第十次會議於2020年12月4日召開,審議通過了《關於公司及子公司申請2021年度銀行授信及相關授權的議案》。
根據公司2021年生產經營及發展的需要,公司及子公司山東藍帆新材料有限公司(“藍帆新材料”)、Omni International Corp. (“Omni”)、Biosensors International Group, Ltd. (“柏盛國際”)擬向各商業銀行申請綜合授信額度共計14.425億元人民幣和2000萬歐元,2021年內公司及子公司將根據實際生產經營需要適時向各銀行申請貸款。
具體融資金額將視公司及子公司的生產經營對資金的需求來確定,且不超過上述具體授信額度;貸款期限、利率、種類以簽訂的貸款合同為準。公司董事會授權管理層辦理公司一切與銀行借款、融資等有關的事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.